Certara’s QSP modeling platforms for neuroscience are designed to address the unique challenges of neuro indications. By incorporating critical biology relevant to brain function and cognition, these platforms enhance the probability of successful neuroscience drug discovery. Neurological diseases often involve complex etiologies, heterogeneous populations, and reliance on indirect biomarkers, making drug development particularly challenging. Certara’s QSP models enable in silico studies to simulate population dynamics, virtual patients, and biomarker effects, ultimately informing dosing strategies, patient selection, and clinical trial design.
QSP Modeling Platforms for Neuroscience
Advancing therapies with mechanism-based models for Alzheimer’s, Parkinson’s, and more
Learn more about QSP modeling platforms for neuroscience
アルツハイマー病: Customizable modules for hypothesis testing and therapeutic comparisons.
パーキンソン病: State-of-the-art models for cognitive outcomes and symptom management.
Psychotic Disorders: Advanced modeling for understanding disease mechanisms and treatment effects.
Certara's experience in neuroscience QSP projects
Our neuroscience QSP team has worked on projects involving various neurodegenerative diseases.
75
Neuroscience QSP modeling projects
37
Alzheimer’s disease publications
13
Parkinson’s disease publications
20
Psychotic disorders publications
Alzheimer’s disease 34%
Parkinson’s disease 16%
ALS 9%
Mood & psychiatric disorders 9%
Pain 8%
Narcolepsy 5%
Other 14%
Epilespy 2%
Multiple sclerosis 1%
QSP modeling for Alzheimer’s disease
Certara’s QSP model for Alzheimer’s disease comprises of individual modules that can be mixed and matched to build a customized model to address specific hypotheses and be used to compare novel therapeutics with current competitors on the market. Incorporating quantitative strategies maximizes model-informed drug development decisions.
Custom mechanisms
Comedications
APOE
Neuroinflammation
Neuroanatomy
Cognition
Amyloid
Tau
Characteristics
- Aβ and tau pathology
- Disease progression
- BOLDfMRI
- Comedications and Standard-of-care (SoC) medication
- Tau propagation
- Adverse events (ARIA incidence)
- Genotype (ex. APOE, 5HT-R, DA-R)
- Brain electrophysiology: circuit, neuron, and receptor activity
Biomarkers/readouts
- CSF and plasma biomarkers
- Aβ42/40, p-tau, t-tau levels
- Imaging biomarkers (PET SUVR/centiloids)
- Volumetric Brain Changes (MRI)
- Microglial activation
- Cytokine release
- Brain Activity
- Cognition (e.g. CDR-SOB, ADAS-Cog)
- Agitation (CMAI-ABID)
Drug modalities
- Monoclonal antibody
- Bispecific antibody
- Small molecule
- Prodrug
- ASO
- Gene Therapy
- BBB shuttle
QSP modeling for Parkinson’s disease
Certara’s QSP model for Parkinson’s disease is state of the art and leading the advancement of QSP modeling in the field. Our detailed QSP model of the key brain systems involved in Parkinson’s disease allow us to examine how our partner’s therapy can treat disease symptoms and ultimately affect cognitive outcomes (ex. UPDRS – Unified Parkinson’s Disease Rating Scale).
Characteristics
- Anatomical connectivity
- Clinically relevant neuronal firing property (LFP in STN)
- Standard-of-care (SoC) medication
- Alpha-synuclein pathology
Biomarkers/readouts
- CSF a-synuclein dynamics
- UPDRS Changes
- Time Off Changes
- Power spectrum of LPF in various basal ganglia regions
- BOLDfMRI
Drug modalities
- Optimized for augmentation therapy
- Effect of PK properties on Time-Off optimization
- Simulating PD-PD interactions of disease-modifying drug with SoC on functional outcomes
Meet the QSP experts
1 / 3
エキスパート
Hugo Geerts, PhD
Head of Neuroscience Modelling, QSP
In Silico Biosciencesの共同創設者として、神経学や精神医学分野のQSPモデリングに18年間取り組んできました。また、ベルギーのべーアセに拠点を置くJanssen Research Foundationのリサーチフェローとして創薬と開発業務に20年間携わってきました。サターラでは、神経変性疾患を対象とした新たなQSPコンソーシアムを先導する役割を担っています。...
専門家に相談する
2 / 3
エキスパート
Shaina Short
Sr Scientist, QSP R&D
With a Ph.D. in Neuroscience and over 15 years of experience in neuroscience QSP and computational neuroscience modeling, Shaina leads consultancy and the development of neurodegenerative and neurological QSP modeling platforms at Certara, advancing therapies from early discovery to market competition.
専門家に相談する
3 / 3
エキスパート
Sarah DiBartolo
Sr Scientist, QSP Consultancy
With 10+ years experience, Sarah’s expertise in QSP modeling spans the entire drug development pipeline, from early feasibility assessment to clinical and post-market analyses, with a focus on Alzheimer’s Disease.
専門家に相談する関連情報
全て見るExplore our other QSP platform models
サターラは、多様な治療領域に対応する定量的システム薬理学（QSP）プラットフォームモデルを提供しており、データ主導のインサイトにより医薬品開発の加速化を実現しています。当社のカスタマイズされたソリューションは、複雑な生物学的システムを統合し、研究および臨床現場における科学的な意思決定をサポートします。
Speak to a QSP expert
Discover how Certara’s QSP modeling platforms for neuroscience can accelerate your therapies.
Tailored solutions for Alzheimer’s, Parkinson’s, and other neuro indications
Advanced simulation tools for patient-centric outcomes
Expertise in addressing complex neurodegenerative challenges
